← Back to all substances
A

insulin

184ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: Insulin Analog [EPC]

1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Known as: ADMELOG
Route: INTRAVENOUS, SUBCUTANEOUS
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
139,975
Total in FDA
86%
Serious Reports
91
Fatal Outcomes

Seriousness

Serious
432
Non-Serious
68

Sex Distribution

Male
231
Female
244
Unknown
25

Age Distribution

0-17
10
18-40
35
41-64
184
65-84
158
85+
20
Unknown
93

Outcomes

Recovered/Resolved
374
Recovering/Resolving
124
Not Recovered/Not Resolved
336
Recovered with Sequelae
12
Fatal
91
Unknown
931

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-adfcf5
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...